



Press Release

ProStrakan Group plc

ProStrakan Announces LG Life Sciences as South Korean Partner for Sancuso®

Galashiels, Scotland, 13th August 2007 ProStrakan Group plc (LSE: PSK), the European specialty pharmaceutical company, today announces that it has signed an exclusive distribution agreement with LG Life Sciences, Ltd. ("LGLS"), a leading pharmaceutical company in South Korea, for Sancuso®, ProStrakan's transdermal granisetron patch for the prevention of chemotherapy-induced nausea and vomiting.

Under the terms of the agreement, ProStrakan will receive upfront and milestone payments, subject to the achievement of certain approvals and sales targets, of up to \$6 million. ProStrakan will exclusively supply Sancuso to LGLS and will receive an undisclosed royalty rate on sales generated in South Korea by LGLS. ProStrakan submitted a New Drug Application (NDA) to the U.S. Food & Drug Administration (FDA) in June 2007 and a marketing authorisation application across Europe in July 2007. Following FDA approval in the US, LGLS will seek approval of Sancuso in South Korea.

Many patients undergoing chemotherapy experience acute nausea and vomiting, either immediately after chemotherapy or for up to five days thereafter. ProStrakan's transdermal patch delivers granisetron, an established 5-HT₃ receptor antagonist which treats this side effect, steadily into the bloodstream without the need for injection or having to swallow pills. ProStrakan announced positive results from the pivotal Phase III programme on Sancuso in patients undergoing multi-day chemotherapy in December 2006.

Commenting on today's announcement, Dr Wilson Totten, ProStrakan's Chief Executive, said:

"In addition to building our own sales forces, we are growing a meaningful revenue stream from outlicensing our product portfolio in markets where we do not intend to build a direct commercial presence. Our partnership with LG Life Sciences is another clear example of this, capitalising on the global value of Sancuso, our latest product to reach the registration stage. In LGLS we have a recognised partner who will work with us to commercialise Sancuso in South Korea, an important and dynamic market, and help us establish this product as a valuable treatment for chemotherapy patients at risk of nausea and vomiting."

Ends

For further information, please contact:

ProStrakan

+44 (0)1896 664000

Dr Wilson Totten, Chief Executive
Paul Garvey, Chief Financial Officer
Callum Spreng, Corporate Comms Director

Financial Dynamics

+44 (0)20 7831 3113

David Yates / Ben Brewerton

ProStrakan

ProStrakan Group plc is a rapidly growing specialty pharmaceutical company engaged in the development and commercialisation of prescription medicines for the treatment of unmet therapeutic needs in major markets.

ProStrakan's head office and development facilities are situated in Galashiels in Scotland. EU-wide sales and marketing of ProStrakan's portfolio of products are handled by commercial subsidiaries in the UK, France, Germany, Spain and other EU countries.
www.prostrakan.com

LG Life Sciences

LG Life Sciences, Ltd., an LG affiliate, is a leading pharmaceutical company in South Korea.

LG Life Sciences is committed to promoting health and well-being of patients and customers. LG Life Sciences offers global brand products, such as Valtropin® (hGH) and Factive® (gemifloxacin), and other medicines for metabolic and cardiovascular diseases as well as infectious and liver diseases.

LG Life Sciences strives to be a global leader in bio-healthcare. Additional information is available at **www.lgls.com**.